Aperiomics, a biotechnology company that saves lives by harnessing next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test to pinpoint the causes of infectious disease, today launched its new website – http://www.aperiomics.com -- an information portal for clinicians, patients and researchers.
Aperiomics is one of the rising stars of the biotech industry. The company is growing quickly and has drawn attention not only of the medical industry but investors as well. Over the first six months of 2017, Aperiomics grew its customer base ten-fold. Revenue over the same period alone was higher than the entirety of the company’s revenue since it started in 2014. Aperiomics has received more than $1.6 million in grants from the National Science Foundation – the latest, a grant to further develop its pathogen identification platform.
Among customers that Aperiomics has helped are hundreds of patients for whom doctors could not find a solution to their illnesses until their samples were analyzed by Aperiomics to detect which pathogens were responsible. For some it was a life-death issue. Americans spend $200-250 billion per year on medical diagnostic testing according to the American College of Physicians. Much of that testing uses old technology and guesswork, leading to wasted time, money and chronic infection.
“Aperiomics is at the forefront of a very exciting worldwide expansion of technology in medicine,” said company CEO Dr. Crystal Icenhour. “Because of our powerful technology and the expert team we have in place, medical professionals and patients put their confidence in Aperiomics to find answers that no one else can find.”
The new Aperiomics website provides specific information on services for clinicians, patients and researchers:
- For clinicians, Aperiomics solves inadequate pathogen testing by using deep next-generation sequencing and the Aperiomics Microbial Database™ (the world’s largest collection of pathogens) to test for everything instead of only a few things at a time.
- For patients, Aperiomics can help their doctors provide faster wellness through more accurate identification of the causes of infectious diseases.
- For researchers, next-generation sequencing and bioinformatic services can be customized for all pathogen testing and microbiome characterization work. Aperiomics has worked with many organizations to support genetic monitoring, biosurveillance, pathogen identification, microbiome characterization and quality monitoring programs.
Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.). The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others. Aperiomics was named Life Sciences Innovators of the year in 2016 and as a finalist in the 2017 Greater Washington Innovation Awards. For more information, visit www.aperiomics.com or call (703) 229-0406.